{"name":"Prelude Therapeutics","slug":"prelude","ticker":"PRTX","exchange":"NASDAQ","domain":"preludetx.com","description":"Prelude Therapeutics is a precision oncology company focused on developing innovative therapies for patients with cancer. The company's pipeline includes several promising candidates, including PRMT5 inhibitors and other targeted therapies. With a strong focus on precision medicine, Prelude Therapeutics aims to improve patient outcomes and quality of life. As a relatively new player in the oncology space, the company is poised for growth and expansion.","hq":"Wilmington, DE, USA","founded":0,"employees":"","ceo":"Kris Bhatt","sector":"Precision Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$280M","metrics":{"revenue":12140000,"revenueGrowth":73.4,"grossMargin":0,"rdSpend":94300000,"netIncome":-99498000,"cash":141315000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"PRTX-132 patent cliff ($0.00 at risk)","drug":"PRTX-132","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"PRTX-153 patent cliff ($0.00 at risk)","drug":"PRTX-153","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Prelude Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Prelude Therapeutics reported its fourth quarter and full year 2023 financial results, highlighting progress in its pipeline and financial performance.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Prelude Therapeutics Announces Collaboration with Merck KGaA to Develop PRMT5 Inhibitors","summary":"Prelude Therapeutics entered into a collaboration with Merck KGaA to develop PRMT5 inhibitors for the treatment of cancer.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"trial","headline":"Prelude Therapeutics Announces Initiation of Phase 1 Clinical Trial of PRTX-132","summary":"Prelude Therapeutics initiated a Phase 1 clinical trial of PRTX-132, a novel PRMT5 inhibitor, for the treatment of cancer.","drugName":"","sentiment":"neutral"}],"realNews":[{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-10","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-12","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"}],"patents":[{"drugName":"PRTX-132","drugSlug":"prmt5-inhibitor","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"PRTX-153","drugSlug":"prmt5-inhibitor","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Precision Oncology","Cancer Therapeutics"],"financials":{"source":"sec_edgar+yahoo","revenue":12140000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":12140000,"period":"2025-12-31"},{"value":7000000,"period":"2024-12-31"},{"value":7000000,"period":"2024-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":94300000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-99498000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":141315000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}